cyrilzakka/clinical-trials huggingface dataset:
COmparisoN of High-sensitivity Cardiac TRoponin I and T ASsays Trial

Compare the analytical and clinical performance of hs-cTnI and hs-cTnT assays for the diagnosis of acute myocardial injury and myocardial infarction in patients presenting to the emergency department in whom serial cTnI measurements are obtained on clinical indication.

Background: Comparative studies addressing the analytical and clinical performance of hs-cTnI and hs-cTnT assays for the diagnosis of acute myocardial injury and myocardial infarction in consecutive patients presenting to a United States (US) emergency department are lacking.

Study objective: Compare the analytical and clinical performance of hs-cTnI and hs-cTnT assays for the diagnosis of acute myocardial injury and myocardial infarction in patients presenting to the emergency department in whom serial cTnI measurements are obtained on clinical indication.

Null Hypothesis: hs-cTnI and or hs-cTnT assays will offer comparable diagnostic performance for acute myocardial injury and acute myocardial

Eligibility Criteria:
Inclusion Criteria:

1. Adult, defined as subject 18 years of age or older
2. Baseline cTn measurement and at least one additional cTn measurement within 6 hours after initial cTnI measurement.
3. At least one 12-lead electrocardiogram

Exclusion Criteria:

1. Currently pregnant
2. Trauma related admission
3. Cardiac arrest
4. Decline to participate
5. Did not present through the ED
6. Transferred from an outside hospital
A Phase IIIb Study of Intermittent Versus Continuous Hormone Deprivation Treatment With ELIGARD

Phase IIIb, Open-label, randomized, controlled multi-centre study. Induction therapy phase for 6 months where all subjects receive 2 ELIGARD depot injections. Those subjects with hormone responsive prostate cancer will be randomized and will receive either intermittent or continuous ELIGARD treatment for 36 months. Following this treatment period, subjects will enter a long-term follow-up period for 48 months.


Eligibility Criteria:
Inclusion Criteria:

At study entry (visit 1):

* Written informed consent
* Male subjects aged \>=18 and \<80 years old
* Locally advanced (stage T3 or T4) prostate cancer or Relapsing prostate cancer following radical prostatectomy or,Relapsing prostate cancer following radiotherapy
* Gleason score of \>=6
* ECOG performance status of 0-2.
* Life expectancy at least 5 years

At randomization (visit 4):

* Two successive decreasing serum PSA levels \<=1 ng/ml

Exclusion Criteria:

At study entry (visit 1):

* Any suspected second primary tumors
* Evidence of metastatic disease
* Other malignancy within the last 5 years except
* Acute spinal cord compression, uni- or bilateral ureteric obstruction
* Any concurrent biological response modifier therapy
* Concurrent chemotherapy
* Less than 1 year since any prior neoadjuvant or adjuvant hormonal therapy
* Less than 6 months since prior 5-alpha reductase inhibitor treatment
* Other concurrent hormonal therapy
* Any concurrent radiotherapy
* Testosterone at screening \<= 1.7 mM or 50 ng/dL
* Clinically significant elevation of serum creatinine or liver enzymes
* Hypersensitivity to GnRH or other GnRH analogues or leuprorelin acetate
* Hypersensitivity to CASODEXâ 50 mg.
Genetic Basis of Hemangiomas

The purpose of this study is to determine if there are genes that are common in children with infantile hemangioma. This information will allow physicians to improve care for patients who have been diagnosed with this disease and to provide their parents with more complete information regarding the cause of this disease. This research is being done because many unanswered questions remain regarding children with infantile hemangioma. There are very few medications to treat infants with hemangiomas.

WHAT IS INVOLVED IN THE RESEARCH STUDY?

* Buccal smear (cheek cells) or small blood sample (4 mL or 1 teaspoon) from child being seen in the Dermatology clinic having infantile hemangioma or vascular anomaly
* Buccal smear (cheek cells) or small blood sample (4 mL or 1 teaspoon) from parents of child

If you and your child agree to be in this study, the following will happen:

1. Informed consent and permission to use or disclose your/your child's health information for research purposes will be obtained by Dr. Drolet, the principal investigator, or her research team. You will receive a copy of this consent form.
2. A buccal swab or blood sample will be obtained from you and your child; buccal sampling involves rubbing the inside of your cheek and removing cells to perform a genetic test called "Genomewide Association (GWA).

We expect you and your child to be involved in this study until you and your child have the genetic testing performed.

Eligibility Criteria:
Study Population Inclusion Criteria:

* No limit to age
* Diagnosis of infantile hemangioma and/or vascular anomaly
* Unaffected twin sibling
* Each patient's authorized legal guardian must understand the nature of the study and must provide written informed consent. Each patient must also give assent to study participation.

Study Population Exclusion Criteria:

* Diagnosis other than infantile hemangioma or vascular anomaly
* If the lesion has resolved and cannot be confirmed as a hemangioma by clinical exam
* If the biologic parents are unwilling or unable to submit DNA samples the child will be excluded from the DNA study. Therefore, if DNA samples cannot be or are not obtained from both biologic parents, the child and family will be excluded from the study.
Integrative Medicine for Hospital Workers Exposed to War

During the "Iron Swords" war in Israel in 2023, the residents of the Gaza Strip and the surrounding area, along with the soldiers of the security service, were exposed to a very high intensity of trauma. Added to this is an extensive cycle of trauma for those who were directly and indirectly exposed to loss and terror throughout the country. Medical teams in the hospitals and in the community were exposed with the highest intensity to these traumatic aspects which were amplified by the collapse of many of the resilience and mental health centers in the south.

An integrative medicine treatment clinic was established at the Bnai Zion Medical Center for the purpose of providing a response to all hospital employees who are exposed and will be exposed (directly or indirectly) to the wounded and patients expressing trauma, including symptoms of acute stress disorder, as a result of war and terrorism. Hospital employees are invited to register for complementary medicine treatments on the hospital's website according to indications that include anxiety, emotional distress and/or typical Acute Stress Disorder (ASD) symptoms, including physical distress (such as pain, breathing disorder, digestive system symptoms, exhaustion, etc.). The employees are treated by a team from the system for integrative medicine, including practitioners of acupuncture; touch/movement techniques (for example, qigong, reflexology, shiatsu) or mind-body medicine (for example, relaxation and breathing exercises) and may include one or more of the above 3 treatment areas.

In the proposed study, the investigators plan to examine the effect of these treatments on various symptoms experienced by hospital employees during this period.


Eligibility Criteria:
Inclusion Criteria:

* Hospital employees
* Anxiety, emotional distress and/or typical ASD symptoms directly or indirectly related to exposure to the trauma of terrorism or war

Exclusion Criteria:

* None
10 Years Evaluation of Composite Restoration

This randomised, split-mouth clinical study evaluated the marginal quality of direct Class I and Class II restorations made of microhybrid composite and applied using two polymerisation protocols,


Eligibility Criteria:
Inclusion Criteria:

* subjects at least 18 years old,
* require restorations due to primary caries in contralateral quadrants with opposing and adjacent tooth contact,
* having no restoration in the antagonist,

Exclusion Criteria

* allergic to resin-based materials,
* pregnant or nursing,
* periodontal disease
The Immediate Effects of Tissue Flossing on Knee Flexion Range of Motion

The purpose of this study is to verify the immediate effects of Tissue Flossing on knee flexion range of motion

After completing the questionnaire, 58 healthy participants will be randomly divided into two groups named Intervention Group (IG) (n=29) and Control Group (CG) (n=29).

In the first assessment (M0), knee flexion ranges will be measured using a goniometer. Then the control group (n=29), without Tissue Flossing and intervention group (n=29) with Tissue Flossing around the knee joint will be subjected to passive and then active mobilization of the knee joint. Immediately after the intervention/control, the two groups will be assessed again (M1).

Eligibility Criteria:
Inclusion Criteria:

* healthy people between 18 and 35 years old with normal mobility of the joints of the lower limbs of the body.

Exclusion Criteria:

* deformities in the region of the lower limbs of the body, complaints in this region in the last 6 months, surgical procedures, venous thrombotic disease, heart disease, respiratory disease, or neurological, orthopedic, dermatitis, or neuromuscular problems in the lower quadrant that may disrupt musculoskeletal function. Also high blood pressure, latex allergies, lymphedema and individuals taking anticoagulant medication, and cortisteroid therapy.
Optimal Timing of Zoster Vaccine After Zoster Illness

The purpose of this study is to determine the optimal timing of zoster vaccination to induce both higher cell-mediated immunity and humoral immunity in adult patients aged over 50 with history of zoster within 5 years.

Zoster vaccination is recommended by FDA for adults aged 60 years or older, and is approved for people aged 50 through 59 years old. For patients who had shingles, there is no specific length of time they must wait before receiving shingles vaccine. It is generally recommended that patients should wait for 6 to 12 months after recovery.

The investigators plan to make scientific recommendation for optimal timing of zoster vaccine after zoster illness by comparing immune response between two groups (vaccination at 6 months to 2 years after shingles vs. 2 to 5 years after shingles). Primary outcome is ELISPOT response at week 6 after vaccination. Secondary outcome is gpELISA titer at week 6 after vaccination.

All the patients will be asked if they have any contraindications for zoster vaccine by a physician before vaccination. And they will be monitored for any adverse reaction of the vaccination after 6 weeks (visiting the hospital).

Eligibility Criteria:
Inclusion Criteria:

* Adults aged 50 years or older who have had shingles in 5 years
* Adults who did not receive zoster vaccination yet
* Adults who can understand and agreed with the informed consents.

Exclusion Criteria:

* Adults who have conditions which is contraindication for zoster vaccine
* Adults who had zoster vaccination already
* Adults who take immunosuppressants
* Human Immunodeficiency Virus (HIV) patients whose CD4 T cell counts below 500/mm3
* Adults with autoimmune disease who are anticipated to have a problem with immunogenicity for vaccine
* Adults who had organ transplantation and receive immunosuppressants
* Adults who are suspected to have active infectious disease
* Adults who are not eligible for zoster vaccination by investigator's assessment
Video Laryngoscope, New Intubation Device

new glidoscope was tested on 401 patients

Four hundred and one patients who were scheduled for elective operation, were randomly assigned to be intubated by direct laryngoscopy using a Macintosh blade size 3rd (DL, n=196) or intubation using the video laryngoscope (VL, n=205). Prior to intubation all patients were given a similar regimen of induction of anesthesia. The patients were then intubated, using direct laryngoscopy or the VL, by a different anesthetist during which the larynx was inspected and given a laryngoscopy score. Time to intubate, failure rate, injuries, personnel pleasure and, aspiration rate were measured

Eligibility Criteria:
Inclusion Criteria:

* elective operation who filled the consent

Exclusion Criteria:

* poor intubation
* emergency cases
* hemodynamic derangement
Clinical Trial of YH14618 in Patients With Degenerative Disc Disease

Research Hypothesis:

There will be a greater proportion of VAS responders defined as those who achieve ≥ 50% reduction from baseline in VAS for low back pain at week 12 following intradiscal injection of YH14618 compared to placebo. Patients have been diagnosed as one or two symptomatic lumbar degenerative disc disease defined as Pfirrmann grade 2 to 4 using MRI. Patients have suffered from persistent low back pain with at least 3 months of conservative therapy and must have low back pain measured by VAS≥4 cm and modified Oswestry disability index (mODI) ≥30% at the baseline.


Eligibility Criteria:
Inclusion Criteria:

* Patients diagnosed as one or two symptomatic early lumbar (L1/L2 \~ L5/S1) degenerative disc disease defined as Pfirrmann grade 2 to 4 using MRI performed within 4 weeks prior to randomization.
* Patients have suffered from persistent low back pain with at least 3-month conservative therapy.
* Patients have low back pain measured by VAS≥4cm and mODI≥30% at screening and randomization visit (Day 0).

Exclusion Criteria:

* Clinically significant spine compression fracture, spinal stenosis, or spinal instability.
* Clinically significant sacroiliac joint dysfunction, facet joint pain, or those who are suspected.
* Modic change type III assessed by X-ray and MRI
* History of spine surgery
* Neurologic disorders.
* Any other systemic disease which can influence spine such as rheumatoid arthritis, ankylosing spondylitis, or autoimmune disease.
* Participation in other clinical trials with intradiscal injection (eg, Phase 1/2a YH14618-201 trial, or Cell therapy, etc.)
Etiologies, Definitive Diagnosis and Patient Outcomes in Altered Level of Consciousness in the Emergency Department

When someone starts acting differently in terms of how alert or awake they are, it can be a tough situation for emergency (ER) department doctors.e exact and definitive etiologies of ALOC that can be intracranial or extracranial.

The change in terms of mental state in accordance with how alert and awake patient is termed as altered level of consciousness. Etiologies will be classified by using convenience sampling. GCS\<14 patients will be included in this study. Data will be collected through a slight modification in a pre-designed Performa. Reference point for the data collection will be the time of discharge from the emergency department. In Previous studies mostly, etiologies were classified as extracranial and intracranial. Some studies found neurological etiologies most dominant as an extra cranial and some studies found systematic infections ,metabolic causes and some demonstrated that intracranial etiologies were dominant. So, in this study we will find the definitive diagnosis in patient having ALOC which can be intracranial or extracranial. And also, it will be compared with GCS scale. This study will identify th

Eligibility Criteria:
Inclusion Criteria:

* Patients with GCS\<15, age group 18 years to 90 years which come in emergency department due to any etiology will be included in this study.

Exclusion Criteria:

* GCS = 15 will be excluded from the study.
* patients coming in any outpatient department setting or other than emergency department and age group \<18 or \> 90 will be excluded from this study.
Controller Medications in the Management of Bronchial Asthma

The purpose of this study is to know the effect of another controller medication add on to the inhaled corticosteroid and long acting β2 agonist on clinical symptom, lung function and compliance in patients of moderate to severe persistent bronchial asthma.


Eligibility Criteria:
Inclusion Criteria:

* aged between 15 to 65 years of either sex
* had clinically diagnosed Bronchial asthma
* had poor asthma control defined by ACQ score (asthma control questionnaire) of 1.5 or greater
* FEV1 (Forced Expiratory Volume at 1 second) value of 50% or more of predicted
* improvement in FEV1 was greater than 15% after bronchodilator inhalation

Exclusion Criteria:

* major illness of system other than respiratory major respiratory illness other than asthma taken long acting anti histaminic within a preceding week of enrollment Smokers Pregnant and lactating woman history of hypersensitivity to any of above drugs
Investigation of Endotracheal Cuff Pressure Changes According to Different Positions in Neurosurgery Cases

We aimed to measure the change in cuff pressure in different positions in neurosurgery cases and to investigate the effect of case length on cuff pressure.

It is an observational study, the cuffs of the endotracheal tubes of the patients who were intubated under general anesthesia between February 2023 and May 2023 will be inflated at 25 cm H2O pressure, and then the pressure line and the pilot balloon will be connected to the anesthesia monitor. The cuff pressure of the patient will be measured from the pilot balloon throughout the case and recorded at half-hour intervals. Postoperative sore throat will be evaluated on the VAS scale. Postoperative cough, hoarseness, and dysphagia symptoms will be evaluated.

Eligibility Criteria:
Inclusion Criteria:

* Neurosurgery patients between the ages of 18-70 ages
* American Society of Anesthesiologist score I-II-III-IV

Exclusion Criteria:

* Patients with previous tracheostomy
* Patients with tracheal stenosis
* Patients considered as difficult intubation
* Patients who have had more than one intubation attempt
* Patients with an ASA score greater than 4
* Patient who has difficulty understanding visual analog scale (VAS) scores
* Language / communication barrier
* Patients younger than 18 years old
Optimized Treatment Strategy for HighGrade1 (HGT1) Bladder Cancer Based on Substaging: a Prospective Observational Cohort Study

Non-muscle invasive bladder cancer of High Grade stage T1 (HGT1), has up to 20% risk of progression to invasive disease. Because the depth of substaging seems to identify two separate groups with different progression risk (HighGradeT1a and HighGradeT1b), we design a differential treatment strategy for each group. The main hypothesis is that HighGradeT1a bladder cancer can spare a second endoscopic procedure.

Only cases of initial diagnosis of HighGradeT1 and with a complete transurethral endoscopic resection (TUR) of bladder tumor) can enter this protocol. HighGradeT1a will only receive standard BCG treatment (induction and maintenance). HighGradeT1b will undergo a second transurethral endoscopic resection (TUR) after the induction of Bacillus de Calmette-Guerin (BCG) and then continue mantenaince BCG and standard follow-up.

Eligibility Criteria:
Inclusion Criteria:

* HGT1 bladder cancer at initial diagnosis and after a complete TUR

Exclusion Criteria:

* abscence of muscularis propria in the TUR specimen
Effectiveness of the Combination of Water Aerobics and Metacognitive Training

The objective of this study is to assess the efficacy of a combined intervention of water aerobics and Metacognitive Training (MCT), compared to each intervention separately, in people with psychosis. One purpose is to analyze the improvement of clinical, cognitive, metacognitive and psychosocial variables, motor coordination and physical health condition. Another purpose is to study the changes in SP1 and SP4 biomarker transcription levels as a function of the intervention received. The hypothesis is that the combined intervention will enhance the benefits of each intervention separately, specifically in symptoms, cognition, metacognition and psychosocial variables.


Eligibility Criteria:
Inclusion Criteria:

* Presence of one of the following diagnoses according to DSM-V criteria: schizophrenia, unspecific psychotic disorder, schizoaffective disorder, delusional disorder, brief psychotic disorder, schizophreniform disorder.
* Psychopatological stability
* 18 to 55 years old
* Interested in participating in both water aerobics and MCT groups

Exclusion Criteria:

* Head injury or intellectual disabillity (premorbid IQ \<=70)
* Present scores on the PANSS \>=5 in hostility, lack of cooperation or suspiciousness, to guarantee a good relationship in the group
* Patients with substance dependence disorder
* Problems related to water activities (phobia, severe mobility problems...)
Pilot Study for the Application of Low Power External Bioelectronic Devices in the Diagnosis of Bronchial Asthma.

The objective of this study is to detect the acoustic signals generated by the respiratory system on asthma patients using an acoustic sensor and retrospectively use these signals to identify the characteristics that differentiate patients with asthma and healthy subjects.

The objective of this project is to detect acoustic signals generated by the respiratory system in patients with asthma using the acoustic sensor; and then, retrospectively, to use these signals to carry out signal processing research, with the aim of trying to identify signal characteristics that can be used to differentiate asthma patients from people who do not have the disease.

The hypothesis, therefore, is that it is possible to target through external smart bioelectronic devices and wireless connectivity (wearables) the initial signals of the pathophysiology of bronchial asthma and differentiate them from the signals of the normal respiratory physiology of a healthy individual.

Similarly, detection of such signals would not only be useful for asthma diagnosis but also for monitoring and early detection of exacerbations before they can be detected by the usual respiratory functional tests.

The patients will first visit the asthma unit where the diagnostic tests will be undertaken. Then the subjects will take the acoustic sensor home with them and wear it during sleep for at least two weeks.

Eligibility Criteria:
Inclusion Criteria:

* Male or female, aged \>= 18 and \< 65.
* Ability to access applications on mobile device, technical understanding and minimal technological skills
* Subject has provided informed consent and is willing to comply with the study procedures.

Exclusion Criteria:

* Subject does not consent to the study
* Subject does not comply with inclusion criteria
* Subject has a known allergy to medical adhesives